The ERO1 KO mouse phenotype with respect to matrix staining is further increased when deleting the paralog ERO1B, as well as PRDX4. Together, data generated from mouse KO models suggest that a therapeutic window will be achievable with specific pharmacological inhibition of ERO1A for the treatment of cancer, and that inhibition may reshape the TME landscape. Here, PRDX4 is linked to cancer.